3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
8
Gastrointestinal
8
Head & Neck
7
Dermatologic
5
Gynecologic
2
Genitourinary
2
CNS
2
Breast
2
Sarcoma
1
Conditions
Sarcoma
1336
Glioblastoma
493
Gliosarcoma
470
Osteosarcoma
363
Brain Neoplasms
321
Central Nervous System Neoplasms
276
Astrocytoma
262
Dendritic Cell Sarcoma, Interdigitating
258
Gastrointestinal Stromal Tumors
251
Neoplasms
231
Glioma
229
Lymphoma
226
Neuroblastoma
209
Rhabdomyosarcoma
208
Breast Neoplasms
204
Sarcoma, Ewing
202
Recurrence
202
Burkitt Lymphoma
198
Lymphoma, Non-Hodgkin
196
Precursor Cell Lymphoblastic Leukemia-Lymphoma
195
Oligodendroglioma
192
Melanoma
182
Ovarian Neoplasms
175
Lymphoma, Large B-Cell, Diffuse
173
Neoplasm Metastasis
172
Bone Neoplasms
168
Lymphoma, Follicular
158
Leukemia, Lymphocytic, Chronic, B-Cell
144
Lymphoma, Mantle-Cell
143
Liposarcoma
143
Interventions
pembrolizumab
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Noonan Syndrome
×
Sarcoma
×
Clear all
NCT04670679
2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1
Active not recruiting
90 enrolled